U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07901244) titled 'An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease' on Oct. 22.
Brief Summary: To study the long-term safety and tolerability of BHV-1300
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Graves' Disease
Intervention:
DRUG: BHV-1300
delivered subcutaneously via autoinjector
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Biohaven Therapeutics Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....